Another retrospective study, presented at the American Association for Clinical Endocrinologists 2017 conference, shows the heart protective effects of TRT on men with secondary hypogonadism
Testosterone replacement therapy (TRT) may exhibit a protective effect against myocardial infarction, stroke, and all-cause mortality in men with secondary hypogonadism. The study ultimately included 418 men (median age 53.8 years) exposed to TRT and 283 matched controls (median age 54.9 years). At baseline, the prevalence of established cardiovascular disease was 9.8% vs 12.7%, respectively. The treatment group was followed for a median of 3.8 years compared with 3.4 years for the control group. The event composite outcome in the treatment group was 3.3% compared with 6.4% in the control group, with the investigators ultimately observing a reduction in the odds of the combined cardiovascular end point in the treatment group.
Testosterone replacement therapy (TRT) may exhibit a protective effect against myocardial infarction, stroke, and all-cause mortality in men with secondary hypogonadism. The study ultimately included 418 men (median age 53.8 years) exposed to TRT and 283 matched controls (median age 54.9 years). At baseline, the prevalence of established cardiovascular disease was 9.8% vs 12.7%, respectively. The treatment group was followed for a median of 3.8 years compared with 3.4 years for the control group. The event composite outcome in the treatment group was 3.3% compared with 6.4% in the control group, with the investigators ultimately observing a reduction in the odds of the combined cardiovascular end point in the treatment group.
